Protagen Signs Biomarker Discovery Deal with Pfizer | GenomeWeb

NEW YORK (GenomeWeb News) – Protagen said today that it has entered a collaboration agreement with Pfizer to use its SeroTag technology to identify biomarkers in support of Pfizer's drug development work.

Specifically, the collaboration aims to identify markers for stratifying patient cohorts or predicting patient response to a novel autoimmune disease drug being developed by Pfizer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.